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ABSTRACT 
Objectives: Mammary analogue secretory carcinoma (MASC), initially considered a sub-set 
of acinic cell carcinoma (ACC) harbours an ETV6 translocation [t(12:15)(p13:25q)] and is 
now regarded as a distinct entity.  Several putative markers to differentiate MASC from ACC 
have been reported however, the immunohistochemical profile is still being explored and 
updated.  The purpose of this study was to further explore the cytogenetic and 
immunohistochemical profile of MASC.  
Study design: Cases were analysed for ETV6 translocation using fluorescent in situ 
hybridisation(FISH) and stained for CK8, amylase, mammaglobin, GCDFP15, MUC1, 
MUC4, STAT5a, Ki67 (n=37), CK7, Cam5.2, CK14, SMA, p63, S100, vimentin and DOG-
1 (n=42). Histochemical stains for mucins were also performed and data collected for age, 
gender and site. 
Results: FISH showed nine cases with ETV6 rearrangement and two with increased ETV6 
copies. These eleven cases showed absence of PAS-D resistant granules with 10/11 showing 
strong S100, mammaglobin and Stat5a staining. All ACCs showed diffuse DOG-1 staining 
whereas 8/11 MASCs were negative and three showed only focal DOG1 staining.    
Conclusion: DOG-1 can be used in conjunction with PAS-D, S100 and mammaglobin to 
identify MASCs. Cases with increased ETV6 copies are a novel finding with a similar 
immunostaining profile and should be considered as MASCs.  
Abstract word count- 200 
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INTRODUCTION 
Mammary analogue secretory carcinoma (MASC) was first described in 2010 as a distinct 
salivary gland neoplasm, showing close resemblance to secretory carcinoma of the breast 
(SCB) [1,2]. As well as the histological similarity with SCB, MASC was also shown to 
harbour the t(12;15) (p13;q25) translocation and the resulting ETV6-NTRK3 fusion gene 
[1,3,4,].     
MASC has a similar morphological spectrum to acinic cell carcinoma(ACC) but with 
minimal zymogen granules and, in the past, has probably been  diagnosed as a ‘granule-poor’ 
ACC [5].  Overlapping features are seen with other salivary tumours including 
cystadenocarcinomas and mucoepidermoid carcinoma. Meticulous histological analysis 
coupled with immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) may 
be employed to aid diagnosis. FISH for the ETV6 rearrangement is regarded as the diagnostic 
gold standard, but it is relatively expensive and not universally available, resulting in referrals 
to specialist units with associated delay and cost. IHC has been employed to narrow down the 
provisional diagnosis but to date no markers have been identified which can be regarded as 
specific to MASC. Recently, it was suggested that co-expression of mammaglobin and S100 
is sufficient for a diagnosis of MASC [6]. However, this study investigated nineteen cases of 
MASC, but included only one ACC making the staining specificity somewhat uncertain. One 
suggested criterion is that S100 expression must be strong and diffuse [7], but others have 
shown that S100 can be variably expressed in ACC and other tumours may show strong 
diffuse expression [8]. The correct diagnosis may have implications with respect to clinical 
behaviour and the presence of a specific chromosomal translocation offers a potential target 
for future biological therapy. 
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Recently, DOG-1 (discovered on GIST1) or ANO1 has been reported as a marker for acinar 
differentiation with variable expression patterns and localisation between tumours [9]. It was 
first described as a calcium-activated chloride channel in 2008 and is routinely used in the 
diagnosis of gastrointestinal stromal tumours (GIST) [10-16].  Its expression pattern in 
salivary gland neoplasms is not well established although a recent study showed expression 
in acinar lumens in both normal glands and ACC [13]. 
The aim of this study was to identify a specific IHC signature and compare it with FISH and 
clinical information, to further help differentiate MASC from ACC.  
MATERIALS AND METHODS 
Case selection 
The pathology archives were searched for all cases diagnosed as ACC between 1984 and 
2013.  Cases were reviewed to confirm the diagnosis and ensure sufficient tissue was 
available.  Thirty seven cases diagnosed as ACC were identified as suitable.   Subsequently 
five further cases of confirmed MASC were diagnosed (between 2013 and 2015) and were 
added to the study.  The study was approved by the local research ethics committee.  
Routine microscopy and histochemical analysis 
4m sections were obtained from paraffin blocks and stained for haematoxylin and eosin 
(H&E), mucicarmine, and periodic acid-schiff with (PAS-D) and without (PAS) diastase 
digestion. Relevant clinical data including site, gender and age were also obtained. 
Tissue microarray (TMA) construction 
Tissue micro-arrays (TMAs) were constructed from the original 37 cases, using a manual 
TMA machine (Surgipath, Richmond, USA).  Using the H&E stained sections as a guide at 
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least two representative cores were taken from each lesion. Representative sections from 
normal salivary glands were also included in the TMAs for comparison.  For the five 
additional cases IHC and FISH were performed on conventional paraffin sections. 
Fluorescent in situ hybridisation 
FISH analysis for ETV6 rearrangement was undertaken at the Diagnostic Genetics Service, 
Sheffield Children’s Hospital. A Dual-colour break apart rearrangement probe for ETV6 
(12p13) (Catalogue No. 07J77001, Abbott, UK) was used for this purpose. 
Unless stated otherwise, procedures were performed at room temperature (RT).  Sections 
(4µm thick) were dewaxed, dehydrated and washed prior to heat pre-treatment in 50ml 
Zymed (San Francisco, California, USA) solution at 95˚C for 180 minutes. Slides were 
washed followed by application of 60µl of Zymed digestion enzyme and incubation at 38˚C 
in a wet box for 2 x 30 minutes. Sections were dehydrated using ethanol and air dried before 
probe application. ETV6 probe was prepared immediately prior to use. The sample and probe 
DNA were co-denatured at 72˚C for five minutes and hybridised at 37˚C overnight on a PTC-
200 thermal cycler (MJ Research, Waltham, Massachusetts, USA). The slides were washed in 
50ml of 0.4x saline sodium citrate/Tween20 at 73˚C for two minutes and transferred to 50ml 
2x saline sodium citrate/Tween20 for 30 seconds. Ethanol series dehydration was performed 
as before and the slides air-dried in the dark. Slides were counterstained with DAPI (Vector 
Laboratories, Burlingame, California, USA) and coverslipped.  
At least 50 nuclei for each tissue case were analysed. The normal ETV6 gene is represented 
by a co-localised green and orange signal i.e. fusion signal. Rearrangement of ETV6 is 
indicated by a separation of the green and orange signals. A normal cell would therefore 
show two fusion signals, whereas a cell with an ETV6 rearrangement would show one fusion 
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signal, a green signal and an orange signal. The presence of more than two fusion signals 
indicates an increased copy number of the ETV6 gene.  
Immunohistochemistry 
4m serial sections were deparaffinised in xylene and dehydrated in 100% ethanol followed 
by incubation in 3% methanolic H2O2 for 20minutes to block endogenous peroxidase. 
Antigen retrieval was carried out by microwaving in 0.01M sodium citrate buffer for 8 
minutes. For EDTA retrieval, the buffer comprised 1mM EDTA, 0.05% Tween20 and 1000 
ml distilled water (pH 9.0). Slides were incubated in the buffer at 95ºC for 20 minutes and 
then washed in PBS, blocked with serum for 30minutes and incubated with the primary 
antibodies (Table 1) at 4ºC overnight in a humidified container. Omission of primary 
antibody served as negative control.    
After overnight incubation, unbound primary antibody was washed off. Vectastain Elite kits 
were used for secondary antibody and Avidin-Biotin Complex (ABC) at RT in accordance 
with the manufacturer’s instructions (Vector laboratories). Secondary antibody antibody was 
added for 30 minutes followed by a wash and incubation with ABC for another 30 minutes.  
Vector NovaRED kit (Vector laboratories) was used to stain slides for 5-8 minutes and 
colouring reaction stopped using distilled water. Slides were counterstained with 
haematoxylin, dehydrated in graded alcohols and mounted in DPX. 
Not all cases were stained with all the antibodies, the original cohort of 37 cases was stained 
with all the antibodies listed in Table 1.  The five subsequently diagnosed cases of MASC 
were stained with a more limited range of antibodies used for diagnostic purposes.  The 
number of cases stained for each antibody is indicated in the results. 
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RESULTS 
FISH for ETV6 rearrangement 
ETV6 rearrangement was identified in four of the 37 (11%) retrieved cases and in all five of 
the additionally diagnosed MASC cases (n=9/42). These nine cases exhibited the 
rearrangement in a widespread manner (Figure 1). Two additional cases showed an increased 
number of ETV6 copies (56% and 94% of analysed cells respectively) suggesting a close 
association to MASC (Table 2).  
Using FISH as the criteria for selecting cases of MASC, the cases for further analysis were 
divided into 31 cases of ACC and 11 cases of MASC (Nine with ETV6 rearrangement and 
two cases with increased ETV6 copies).  
Histological features (H&E)                                                                                                       
Majority of MASCs showed a microcystic architecture (n=6) followed by a papillary-cystic 
pattern (n=5) (Figure 2). None of the MASCs exhibited a solid or follicular pattern. Both 
cases with increased ETV6 copy numbers showed a papillary cystic pattern. The predominant 
histological pattern in the ACCs was microcystic (n=13; 42%) followed by the papillary 
cystic variant (n=8) (Figure 2). Six cases were of the solid type and four showed a follicular 
pattern. Extracapsular extension (ECE) was seen in 6/11 and perineural infiltration (PNI) in 
3/11 including one case with increased ETV6 copies. 
Histochemical stains 
PAS-D resistant granules were seen in all cases of ACC (n=31). The staining was focal in 
cases with a papillary-cystic pattern or clear cell change. The luminal secretory material was 
also PAS-D positive, as well as psammomatoid bodies seen in one ACC case. Mucicarmine 
showed a similar staining pattern but a lower intensity.  
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All eleven cases of MASC were negative for PAS-D positive granules but all showed a 
characteristic strong globular staining pattern in microcyst lumens and intercellular spaces 
(Figure 3).  
Immunohistochemistry 
All tumours (n=42) showed strong diffuse staining for CK7, which was also seen in adjacent 
normal salivary gland tissue.  CK8 staining was restricted to ducts in normal glands with 
scattered staining in a proportion of the tumours (n=24/37). Abluminal cells stained for 
Cam5.2 in all cases.  Four ACCs showed diffuse αSMA and CK14 expression in 
myoepithelial cells (4/31; 13%), and diffuse p63 staining was seen in only 2/31 (6.4%) cases.  
Staining for myoepithelial cells was presumed positive in the correct morphological context 
to ensure that stromal staining was excluded. MASCs showed only limited focal staining for 
CK14 in two and αSMA in three of the tested cases whereas p63 was negative. However one 
case with increased ETV6 copies showed diffuse staining for all three (Figure 4). Insufficient 
tissue was available for examination for one case. 
Staining for MUC4, MUC1, amylase and GCDFP15 was done on the initial cohort of 37 
cases (including 6 MASCs). MUC4 staining was seen in ducts and secretory material and 
variably in luminal cells in all cases (n=37, not shown). Variable staining was seen for 
vimentin and MUC1. Luminal and secretory material staining for MUC1 was seen in 21/37 
cases, but was observed in 6/6 MASCs. Staining for amylase and GCDFP15 in the secretory 
material appeared more restricted (6/37 and 10/37 respectively). Luminal GCDFP15 staining 
was seen in only 3/31 ACCs, but in 3/6 MASCs including both cases with increased ETV6 
copies.  
S100 staining was carried out on the whole cohort and was seen in 22/42 cases. Ten MASCs 
(10/11; 90%) including both cases with increased ETV6 copies showed strong and diffuse 
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S100 staining throughout the tumours.   Twenty ACCs (20/31; 65%) showed variable S100 
staining, but this was not as strong or diffuse as in MASCs (Figure 5). Weak cytoplasmic 
staining of acinar, and ductal cells was seen in ACC.  
Eight of the eleven MASC cases (73%) including both cases with increased ETV6 copy 
numbers were completely negative for DOG-1. The remaining three cases (3/11) showed 
only weak and focal luminal DOG-1 staining (Figure 6).  All cases of ACC (31/31) were 
diffusely DOG1 positive with strong apical/luminal and lateral membranous staining of 
acinar cells, and luminal staining in tumours with a microcystic pattern (Figure 7). 
Occasional small ductal structures also showed positive luminal staining.  
All cases in the original cohort of 37 cases were stained for mammaglobin and Stat5a.  Only 
one ACC (1/31; 3%) showed mammaglobin staining and Stat5a was positive in only 8/31 
ACCs.  Mammaglobin and Stat5a were positive in 5/6 cases of MASCs tested in the initial 
cohort of 37 with one case negative for each. Both cases with increased ETV6 copy number 
were positive for mammaglobin and Stat5a.  
Age, gender and site distribution 
A wide age distribution from 12 to 95 years was noted with the mean age in the 5th decade. 
The median age for MASC was 51 years (range 12-80) with a much lower median age in 
females (33 years) compared to males (71.5 years). Both cases with increased ETV6 copies 
were in male patients (aged 62.25 and 84 years). The median age for ACC was 46 years 
which was not significantly different compared to MASC (p=0.19, Student’s T-test). 
There was an almost equal gender distribution between males (n=20; 47.6%) and females 
(n=22; 52.4%) in the cohort overall as well as for MASC (6 males and 5 females). The 
predominant tumour site for the entire cohort was the parotid gland accounting for 61.9% 
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(n=26/42) followed by the submandibular gland (13.15%, n=5/42), soft palate and upper lip 
(7.89%, n=3/42 each). The lower lip and buccal mucosa were involved in 5.26% of cases 
(n=2/42 each). The floor of mouth, tongue and parapharynx were the least prevalent sites at 
2.63% (n=1/42 each). 
The parotid gland was the most commonly involved site for MASC (n=6/11, 55%) with two 
cases seen in the submandibular gland (n=2/11, 18%) and one case each in lower lip, soft 
palate and buccal mucosa (9% each). Both cases with increased ETV6 copies involved the 
parotid gland.  
DISCUSSION 
Malignant salivary gland neoplasms can exhibit overlapping histological features making 
diagnosis challenging. This is particularly true for ACC with multiple variants that may be 
seen in conjunction with each other. PAS-D resistant granules in acinic cells are an important 
diagnostic criteria for ACC, however a granule-poor variant of this tumour has been known 
to exist [5]. A distinct subset of ACC resembling SCB was first reported in 2002 lacking the 
usual zymogen granules and containing bubbly eosinophilic material in variably sized cystic 
spaces [3]. This ‘granule-poor’ variant was established as MASC in 2010 when it was shown 
that it not only resembles SCB histologically but also harbours the same chromosomal 
translocation [1,17].  
The ETV6–NTRK3 gene fusion has been shown in other tumours including congenital 
mesoblastic nephroma, congenital fibrosarcoma and acute myeloid leukaemia [18]. This 
translocation facilitates fusion of the transcriptional regulator (ETV6) with membrane 
receptor kinase (NTRK3) leading to activation of the Ras-MAP kinase (MAPK) and the 
phosphatidylinositol-3-kinase (PI3K)-AKT pathways, subsequently promoting survival and 
proliferation of neoplastic cells.   
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Nine cases within our cohort showed the ETV6 rearrangement confirming a diagnosis of 
MASC. These cases also showed a distinct immunoprofile with strong and diffuse staining 
for S100, mammaglobin and Stat5a consistent with previous reports. However, one case of 
MASC was negative for S100 and variable S100 and Stat5a staining was seen in some ACCs. 
Interestingly, most of the MASCs were also negative for DOG-1with three cases showing 
only weak focal positivity.  In contrast all ACCs showed diffuse strong luminal DOG-1 
positivity in the acini and some ducts. This suggests that DOG-1, in conjunction with S100 
can potentially distinguish between ACC and MASC. DOG-1 is particularly attractive as it is 
readily available and routinely used in laboratories for diagnosis of GIST. 
Two further cases showed an increase in ETV6 copy number. This is a novel finding and may 
represent a simple polysomy for chromosome 12 or segmental chromosome imbalance. These 
two cases exhibited a similar morphology and immunophenotype to the confirmed MASCs 
suggesting that increased ETV6 copy number may be associated with the translocation 
representing an ‘in situ’ or early stage. Copy number genome aberrations have been shown to 
be associated with patient outcome and treatment response in childhood ETV6/RUNX1-
positive acute lymphoblastic leukaemia [19,20]. Alteration in ETV6 copy number has also 
been reported in infantile fibrosarcoma and cellular type of congenital mesoblastic nephroma 
[21]. Further work is required to establish the significance of increased ETV6 copies in the 
context of MASC. However, given the similarity in morphology and immunophenotype, we 
would propose that increased ETV6 copy number can also be used as a criterion for diagnosis 
of MASC. 
S100 staining was seen in 11/31 ACCs but appeared much weaker and restricted compared to 
MASCs. This is in agreement with previous reports showing that diffuse and strong S100 
expression may distinguish MASCs from ACCs [1,7].  Mammaglobin and S100 have also 
been suggested as proxy markers for MASC [22]. However, both can be variably expressed 
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in other salivary gland neoplasms [8, 22]. Furthermore, a recent study has shown that 
mammaglobin expression in MASC can be variable with complete lack of expression in a 
small subset [23]. This is further illustrated by the fact that one of our cases with rearranged 
ETV6 showed no mammaglobin expression. 
The eleven cases proposed to be MASC showed a predominantly microcystic pattern (7/11) 
with the remaining four cases being papillary cystic similar to previous studies [17,22,24,25]. 
PAS-D positive granules were absent in all 11 MASCs indicating its utility to triage cases. 
Shah et al. examined 19 cases negative for PAS-D positive granules and showed that all were 
strongly positive for S100 with 18 exhibiting mammaglobin staining and the ETV6 fusion 
transcript [6]. This suggests that morphological examination along with PAS-D staining and 
appropriate immunohistochemistry might be sufficient to diagnose MASC. Our study 
suggests that absence of DOG1 staining may add further veracity to the use of 
immunocytochemistry in the absence of FISH facilities.  
In agreement with existing knowledge, there was an almost equal gender distribution for 
MASC between males (n=6) and females (n= 5) [1,4,26,27]. A recent systematic review 
reports a slight male predominance for MASC (55%) and an average age of 44.2 years (range 
14-77) [2]. In our study, the median age for MASC was 51 years (range 12-84) with a lower 
age in females (33 years) compared to males (71.5 years). Both cases with increased ETV6 
copies were in male patients (aged 60 and 84 years). 
The most commonly reported site for MASC is the parotid gland (71%) followed by the 
submandibular gland (7%) and other sites including soft palate, buccal mucosa, base of 
tongue and lips [2]. Recently, two cases involving the upper and lower lip have also been 
reported [28]. Bishop et al., suggested that most non-parotid ACCs represent misclassified 
MASCs as 11/14 of their non-parotid cases harboured the ETV6 rearrangement [22]. 
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However, the remaining three MASCs in their study were from the parotid gland and a 
significant proportion of our non-parotid tumours were negative for the ETV6 rearrangement 
suggesting that neither ACC nor MASCs are site restricted.     
There have been 11 reported cases in patients under 18 years of age [6,13,26,29-36]. One of 
our cases with rearranged ETV6 involved a 12-year-old female making this the youngest 
reported MASC in literature. MASC involving the parotid gland in a 13-year-old Taiwanese 
male has been the youngest patient reported to date [26]. In another case involving a young 
patient, MASC in the parotid gland presented as a secondary malignancy in a 14-year old 
male survivor of atypical teratoid rhabdoid tumour [29]. Salivary gland tumours are rare in 
children and our findings suggest that MASC should be considered in the list of salivary 
neoplasms encountered in children. 
Interestingly, six MASCs showed ECE and three showed PNI including one case with 
increased ETV6 copies. Histological features of aggressive behaviour such as ECE and PNI 
are relatively uncommon in MASC, however; they have been reported in some cases [30]. 
Eight of the 11 MASCs including the two ‘in situ’ cases were completely negative for DOG-
1, and three cases showed only weak focal positivity.  This is similar to the findings of 
Chênevert et al. who showed restricted DOG-1 expression in MASC with focal positivity in 
some cases whereas strong and diffuse DOG-1 staining was seen in all ACCs compared to 
other entities [9]. Further characterisation of DOG-1 and mammaglobin expression in other 
salivary tumours would be beneficial for understanding distribution of these markers.  
MASCs have been shown to exhibit a range of clinical behaviours from indolent to highly 
aggressive [2]. Skalova et al., showed that 12/15 patients were disease-free after 22-120 
months follow-up, with local recurrence seen in 3/15 and lymph node metastasis in 2/15 [1]. 
Chiosea et al. showed a mean disease-free survival of 92 months (95% CI, range 71–115) in 
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28 MASC patients and 121 months (95% CI, range 92–149) in 38 patients with ACC 
suggesting a more aggressive disease course for MASC [27]. However, there was no 
significant difference between the two groups. Another study reported local recurrence in 3/9 
cases after a median time of 44 months (range, 10–101) [31]. Out of the 172 MASC cases 
reported in the literature until early 2015, only seven patients died from disease. In two 
patients death followed distant metastases, one had multiple locoregional recurrences, and 
one followed unspecified recurrence [1,4,27]. The remaining three involved the parotid gland 
showing high-grade transformation with an aggressive clinical behaviour [37]. These high 
grade lesions showed strong membrane staining for EGFR and β-catenin, and nuclear 
staining for cyclin-D1 in addition to diffuse staining for S-100. ETV6 gene rearrangement 
was seen in all cases. There was no evidence of mutations for TP53 and CTNNB1 genes or 
copy number aberration of EGFR and CCND1 genes. Patients with high-grade MASC died of 
disseminated disease within two to six years of diagnosis.  
A recent study analysed adipophilin (a lipid marker) expression in MASC showing larger 
lipid droplets in MASC compared to other salivary tumours [23]. Similarly, Carbonic 
anhydrase VI has recently been reported as an acinar marker and was shown to differentiate 
MASC from ACC with a sensitivity and specificity similar to DOG1 [38]. These findings 
suggest potential use of these markers as immunohistochemical tools [23]. Furthermore, two 
cases of non-NTRK gene fusion with ETV6 (ETV6-X fusion) have also been reported which 
appears to correlate with more aggressive histological features such as PNI and LVI [39].   
In conclusion, analysis of 31 ACC and 11 MASCs show a distinctive staining profile for 
MASC.  All MASCs show absence of PAS-D positive acinar granules, but show a 
characteristic strong globular PAS staining in microcysts and intercellular spaces.  An 
immunoprofile of strong positive staining for S100 and mammoglobin with an absence of 
DOG-1 positivity may also be specific in addition to Stat5a and GCDFP-15 being useful 
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markers. The same PAS-D and immunoprofile in cases with increased ETV6 copy number is 
a novel finding suggesting that this molecular change may also be a feature of MASC. 
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FIGURE LEGENDS 
Figure 1. Representative images showing FISH with the Vysis ETV6 probe. A) Nuclei demonstrating 
a non-rearranged ETV6 signal. B) Nuclei demonstrating a rearranged ETV6 signal pattern (n=4/37). 
Green/orange overlapping signals represent intact ETV6, green and orange separated signals represent 
ETV6 rearrangement (n=4). C) Nuclei demonstrating increased copies of ETV6 fusion signal (n=2/42) 
(original magnification x100). 
Figure 2. Photomicrographs showing H&E staining of representative cases. A and B. MASC- 
Microcystic pattern. C. MASC- Papillary-cystic pattern. D. ACC with clear cell change. E. ACC- 
Microcystic pattern. F. ACC- Solid patternt. G. ACC- Follicular pattern.  H. ACC- Papillary-cystic 
pattern. 
Figure 3. Photomicrographs showing PAS-D staining. A and B. MASCs showing lack of PAS-D 
resistant zymogen granules and globular intraluminal PAS-D positive secretions. C and D. ACCs 
showing abundant PAS-D positive cytoplasmic granules. 
Figure 4. Representative photomicrographs showing immunohistochemical staining in MASCs. A 
and B. MASC- Cam5.2. C and D.  The same case with increased ETV6 copy numbers showing 
expression of CK14 (C) and αSMA (D).  
Figure 5. Photomicrographs showing S100 staining in MASCs. A-B. MASC- Micro-cystic variant. C. 
MASC- Papillary-cystic variant. D. No staining was seen in one case with rearranged ETV6.  
Figure 6. Representative photomicrographs showing immunohistochemical staining in MASCs. A. 
DOG-1 in normal salivary tissue.   B-C. Absence of DOG-1 staining D. Focal luminal DOG-1 
staining in one MASC. E-F. Mammaglobin. G. Absence of mammaglobin staining in one MASC. H. 
Stat5a.  
Figure 7. Representative photomicrographs showing immunohistochemical staining in ACCs. A. 
S100. B. Stat5a. C-D. DOG-1. E. GCDFP15. F. Mammaglobin. G. MUC1. H. MUC4.  
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Antibody Dilution Pre-treatment Manufacturer Cat. No. No of cases* 
CK7 1:50 EDTA Dako M7018 42 
CK8 1:200 Citrate Abcam AB2531 37 
Cam5.2 1:100 Citrate BD Bioscience 345779 42 
CK14 1:100 Citrate Abcam AB7800 42 
SMA 1:100 Citrate Dako M0851 42 
P63 1:50 EDTA Dako M7247 37 
S100 1:2000 Citrate Dako Z0311 42 
Amylase 1:200 Citrate Sigma WH0000276M4 37 
MUC1 1:50 Citrate Abcam AB15481 37 
MUC4 1:200 Citrate Abcam AB60720 37 
STAT5a 1:200 Citrate Abcam AB32364 37 
GCDFP-15 1:200 Citrate Abcam AB1319 37 
Mammaglobin 1:200 Citrate Dako M3625 37 
DOG-1 1:100 Retrieval 
Solution pH 6.0 
RE7113, Leica 
Leica 
Microsystems  
NCL-L-DOG-1 42 
      
Table 1. Primary antibodies used in this study with their respective dilutions, antigen retrieval 
methods and manufacturer specifics. * 37 cases represent the retrospective cohort analysed in TMAs.  
42 cases include the five additional MASC cases diagnosed between 2013 and 2015. 
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Table 2. Details of FISH analysis with percentage of abnormal cells showing the ETV6 rearrangement 
or increased copy number. At least 50 nuclei were analysed for each case. 
 
Case number Abnormal cells 
10 90% 
14 96% 
19 88% 
23 88% 
38 74% 
39 80% 
40 92% 
41 96% 
42 35% 
 
 
28 56% increased ETV6 copy number 
20 94% increased ETV6 copy number 
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Statement of Clinical Relevance 
MASC of salivary glands harbours an ETV6 translocation with a suggested aggressive 
clinical course. PAS-D and DOG1 staining can differentiate it from Acinic cell carcinoma. 
Tumours with increased ETV6 copies show a similar immunoprofile and should be 
considered as MASCs. 
 
